21/12/2020 - General information
The Codi Risc research project, coordinated by the IMIM Health Services research group and the Neuroscience research group from the Parc Taulí de Sabadell Hospital Consortium, is launching its new website and intranet. Codi Risc is a research project on the prevention of suicidal behaviour based on the Codi Risc Suïcidi (CRS) programme, which was created and implemented in Catalonia in 2014 by the Catalan Government's Department of Health. The purpose of the Codi Risc project is to study the frequency, as well as the epidemiological, clinical, neuropsychological, and biological risk factors involved in suicide attempts and repeated suicide attempts. It also covers the implementation, effectiveness, and costs of the Catalan Government's Codi Risc Suïcidi programme, as well as the development of personalised suicide risk prediction algorithms aimed at preventing suicidal behaviour.
Més informació "Codi RISC research project launches web and intranet"
17/12/2020 - Covid-19
The lockdown declared on 13th March to halt the spread of COVID-19 had a particular impact on people with cognitive impairment, as revealed by a study published in the journal Frontiers in Neurology, carried out by doctors from the Neurology Service at Hospital del Mar and researchers from the Neurofunctionality and Language Research Group in the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar). Six out of every ten patients analysed suffered a worsening of their pre-pandemic condition, according to their caregivers. The study followed 60 patients from the Neurology Service, with an average age of 75, together with their caregivers. A telephone survey was used to assess the functional and neuropsychiatric changes suffered by the patients, in addition to the extra workload put on the caregivers due to the restrictions caused by the pandemic. Their adaptation to lockdown and the safety measures implemented, possible changes in their place of residence, the medical support they received, falls, interruption of cognitive stimulation programmes, and the loss of daily routines were analysed.
16/12/2020 - Press release
T-cell acute lymphoblastic leukaemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis. A collaborative project between IRB Barcelona's Biomedical Genomics lab, headed by ICREA researcher Núria López-Bigas, Anna Bigas' group at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), and Josep Maria Ribera's lab at the Josep Carreras Leukaemia Research Institute (IJC) has discovered that the cells responsible for resistance to T-ALL treatment in adults are already present in the tumours before diagnosis.
15/12/2020 - Press release
DNA damage levels and the activity of the polymerase enzyme responsible for cell repair (PARP) increase in lung tumours in patients suffering chronic obstructive pulmonary disease (COPD), but not in people who do not have this pathology. This is reflected in work by researchers from the CIBER of Respiratory Diseases (CIBERES) and doctors and researchers from the Hospital del Mar Pneumology Service and the Hospital del Mar Medical Research Institute research group on muscle wasting and cachexia in chronic respiratory diseases and lung cancer (IMIM-Hospital del Mar), published in the journal Cancers This research is of enormous importance given that treating lung cancer with PARP enzyme inhibitors (already in clinical use for other tumours, such as breast and ovarian cancers) is preferentially indicated for patients with an underlying respiratory disease, while the response in people with no COPD is highly controversial.
Més informació "The presence of COPD, a determining factor in lung cancer treatment"
18/12/2020 - Press release
The journal Neurology has just published the most complete and exhaustive study to date on the survival rate and sequelae of patients who suffer a ruptured brain aneurysm, a disease known as subarachnoid haemorrhage. The work was carried out by doctors at Hospital del Mar (from the Neurology, Neurosurgery, Intensive Medicine, Interventional Neuroradiology, Radiology and Anaesthesia and Resuscitation services) and researchers from the Hospital del Mar Medical Research Institute (IMIM). The results show that the strategy implemented in Catalonia to cover emergency care for this condition produces results comparable to those of the most advanced centres in the world. The data analysed corresponds to 311 patients with aneurysmal subarachnoid haemorrhage treated at Hospital del Mar over the last 12 years. The short-term mortality rate is between 8.7% (one week after treatment, during the hospitalisation period), and 18.4% (after three months). One year after the vascular event, this figure reaches 22.9% and, five years later, 29%. Only 7% of the patients who survived after five years presented disabling sequelae. According to several studies, deaths from this pathology around the world are between 11% and 27.5% in hospital and over 30% after three months.
Més informació "Only 7% of patients treated for a brain aneurysm suffer long-term sequelae"
25/11/2020 - Institutional news
The Hospital del Mar Medical Research Institute (IMIM) and the Josep Carreras Leukaemia Research Institute (IJC) have signed a collaboration agreement with the aim of jointly promoting scientific research, teaching and training personnel in the healthcare field, as well as pooling their efforts to efficiently manage public and/or private resources available for biomedical research activities in the field of haematology-oncology.
Més informació "Strategic alliance with the Josep Carreras Foundation for research into haematology"
03/12/2020 - General information
The Catalonian Antidoping Laboratory first obtained the ISO17025 accreditation 20 years ago, in November 2000. The laboratory has been accredited as an anti-doping laboratory since 1985 and is one of 30 laboratories in the world accredited by the World Anti-Doping Agency (WADA). The ISO17025 accreditation of all analytical procedures applied in doping controls was a prerequisite for maintaining doping accreditation from 2001 onwards. ISO17025 is an internationally recognised quality standard designed to guarantee the technical competence of testing laboratories, in other words, to ensure that laboratories deliver accurate, reliable results. In Spain, ISO17025 accreditation is awarded by ENAC (Entidad Nacional de Acreditación), a Spanish Government body.
Més informació "The Catalonian Antidoping Laboratory celebrates 20 years of ISO17025 accreditation."
2/12/2020 - Press release
The article published in the journal World Psychiatry and endorsed by the informal scientific network of the United Nations Office on Drugs and Crime (UNODC) and the World Health Organisation (WHO), and including the United States National Institute of Drug Abuse (NIDA), validates and corroborates the approach to the dual diagnosis implemented at Hospital del Mar for patients being treated for addiction to a substance of abuse who, in addition, suffer another psychiatric pathology. Dual diagnosis is a major health problem that causes, according to the article, an increased number of emergencies in healthcare centres, as well as more psychiatric hospitalisations, a higher risk of relapse into drug use and premature death, including suicide. This has individual and social repercussions, as well as consequences for healthcare systems, and means that a multidisciplinary and comprehensive approach is required. Nevertheless, as the authors of the paper point out, there is a generalised lack of preparedness to deal with this situation.
01/12/2020 - Press release
The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from the Spanish National Innovation Agency to develop an innovative treatment for fragile X syndrome (FXS), the most common form of hereditary intellectual disability. The grant comes from the 2019 "Collaboration Challenges" call for projects of the National R&D&I Programme geared towards societal challenges. The call received 420 applications, 158 of which will be funded.
30/11/2020 - General information
Dr. Dr. María Martínez, head of the neuro-oncology section of the Medical Oncology Service at Hospital del Mar and a researcher in the Cancer Molecular Therapy research group at the Hospital del Mar Medical Research Institute, will chair the Spanish Neuro-Oncology Research Group (Grupo Español de Investigación en Neurooncología; GEINO) for the next two years. Her appointment was confirmed on 27th November at the organisation's assembly, which was held virtually. Dr. Martínez explained that her objective at the head of GEINO is "To maintain and strengthen the execution of clinical trials in neuro-oncology, both for primary central nervous system tumours and brain metastases, and to continue down the same path as the previous chairmanship with regard to the most basic and translational researchers, as well as to build bridges and collaborate with other cooperative groups".
Més informació "Dr. María Martínez, new president of the Spanish Neuro-Oncology Research Group"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
